The November PBAC outcomes have revealed an unwelcome twist for a cystic fibrosis therapy, hope for young people suffering from a rare disease, and the reality that some companies are probably already dealing with the flow-on consequences of next April's 'catch-up' statutory price reductions. …
November outcomes confounded by next April's 'catch-up' reductions
December 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma -
Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant
June 19, 2025 - - Latest News -
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 - - Australian Biotech -
NZ Government expands access to melatonin and psilocybin
June 18, 2025 - - Latest News -
Imugene announces US patent allowance for onCARlytics
June 18, 2025 - - Australian Biotech